Amphotericin B for Non-HIV Cryptococcal Meningitis Patients
Conditions: Cryptococcal Meningitis; Antifungal Agents Interventions: Drug: Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.; Drug: Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks. Sponsors: Huashan Hospital Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 21, 2023 Category: Research Source Type: clinical trials
Study of the Clinical Benefits of Different Formulations of Amphotericin B
Conditions: Efficacy; Safety Sponsors: Qianfoshan Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
Bioequivalence of Amphotericin B Liposome for Injection
Condition: Bioequivalence Interventions: Drug: Amphotericin B liposome for injection; Drug: AmBisome Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People With Cystic Fibrosis
Condition: Cystic Fibrosis Interventions: Combination Product: ABCI; Combination Product: Placebo Sponsors: Cystetic Medicines, Inc.; DevPro Biopharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 6, 2023 Category: Research Source Type: clinical trials
